Arvinas, Inc (ARVN) — 分析摘要
Arvinas, Inc（ARVN）的市值为518.11百万美元，最近一年的营收同比增长了-0.3%。净利润率为-30.8%。当前市盈率为-2.3倍。
核心要点
- 营收同比变化-0.3%
- 净利润率-30.8%
- 市盈率-2.3倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，ARVN的营收增长为-0.3%，市盈率为-2.3倍。
Arvinas, Inc (ARVN)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -283.8% — 严重经营亏损
净利率为 -247.5% — 亏损超过收入（可能含一次性费用）
营收较上一期下降 66.0%。
净利润较上一期下降 173.9%。
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
246
总部
NEW HAVEN, CT
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。